Abstract
Given the limited efficacy of conventional chemotherapeutic agents in non-small lung cancer (NSCLC), targeted therapies are being pursued as potential treatment alternatives. For driver gene-negative NSCLC, the detection of rare gene fusions can improve the patient's chance with medication.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
